# AinB

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ainb

- Industry: Biotechnology
- Headquarters: Seoul, South Korea
- Latest round: Seed (Jan 3, 2023)
- Investors on record: 2

## About

Based in Seoul, South Korea, and founded in 2022, Artificial Intelligence (AI) in Bioscience doing business as AinB operates as an AI-based antibody treatment company. In January 2023, the firm raised its seed funding from investors Yuhan Corporation and Medytox Venture Investment. The company, as of January 2023 is led by its CEO, Park Eun-young, and CTO, Seo Seung-woo.

The company (as of January 2023) is working on the discovery and development of antibodies as treatment using data based AI model. The company aims to discover immuno-oncology antibodies first to build its pipeline and to treat cancer-related diseases.

The company plans to utilize its January 2023 funding to hire employees and secure substances that can be developed as a treatment through antibody discovery based on an AI model.

## Funding rounds

- Seed, Jan 3, 2023 — Medytox Venture Investment, Yuhan Corporation

## Investors

- Medytox Venture Investment (https://capitalatlas.ai/funds/medytox-venture-investment) — Seed
- Yuhan Corporation — Seed